The criteria for avoiding unnecessary computerized tomography and bone scan in staging patients with newly diagnosed prostate cancer: Retrospective study of patients at Matsusaka Chuo General Hospital

Japanese Journal of Urology

Volumn 98, Issue 6, 2007, Pages 764-769

  Matsumura, Yoshiaki ^a   Otani, Takeshi ^a   Yoneda, Tatsuo ^b   Matsumoto, Yoshihiro ^a   Maruyama, Yoshio ^a   Fujimoto, Kiyohide ^b   Hirao, Yoshihiko ^b  

^a Matsusaka Chuo General Hospital   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bone scan; CT; Prostate cancer

Indexed keywords

EID: 35348890107     PISSN: 00215287     EISSN: None     Source Type: Journal    
DOI: 10.5980/jpnjurol1989.98.764     Document Type: Article

References (15)

1. Japanese source
2. Japanese source
3. Osterling, J.E., Martin, S.K., Bergstralh, E.J. and Lowe, F.C.: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA, 269, 57-60, 1993.
4. LEE, N., Newhouse, J.H., Olsson, C.A., Benson, M. C., Patrylak, D.P., Schiff, P.B., Schiff, P.B., Bagiella, E., Malyszko, B. and Ennis, R.D: Which patients with newly diagnosed prostate cancer needa computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology, 54, 490-494, 1999.
5. Yu, KK. and Hawkins, RA.: The prostate: diagnostic evaluation of metastatic disease. Radiol Clin North Am., 38, 139-157, 2000.
6. Japanese source
7. Partin, AW., Mangold LA., Lamm DM., Walsh PC., Epstein JI and Pearson JD: Comtemporary Update of prostate cancer staging nomograms (Patin Tables) for the new millenium. Urology, 58, 843-848, 2001.
8. Engeler, C. E., Wasserman, NF and Zhang, G.: Preoperative assessment of proatatic carcinoma by computerized tomography weakness and new perspectives. Urology, 40, 346-350, 1992.
9. Abuzallouf, S., Dayes, I. and Lukka, H.: Baseline staging of newly diagnosed prostate cancer: A summery of the literature. J. Urol., 171, 2122-2127, 2004.
10. Harisinghani MG., Barentsz J., Harn PR, Deserno WM., Tabatabaei S., Hulsbergen C., Rosette J. and Weissleder R.: Non-invasive Detection of Clinically Occult Lymph Node Metastases in Prostate Cancer. N Engl J Med., 348, 2491-2499, 2003.
11. Kizu H., Takayama T., Fukuda M., Egawa M., Tsushima H., Yamada M., Ichiyanagi K., Yokoyaraa K., Onoguchi M. and Tonami N.: Fusion of SPECT and multidetector CT images for accurate localization of pelvic sentinel lymph nodes in prostate cancer patients. J Nucl. Med. Technol., 33 (2), 78-82, 2005.
12. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol, 145, 313-318, 1991.
13. Osterling, J.E.: Using prostate specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic implications. Urology, 46 (Suppl 3A), 26-33, 1995.
14. Osterling, J.E.: Prostate-specific antigen: a criteria assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 145, 907-27, 1991.
15. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ 2007: Initial prostate cancer Diagnosis, Staging Workup, Recurrence Risk (PROS-1), 6, 2007.